Compare Gilead Sciences, Inc. (GILD) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Synchrony Financial — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Synchrony Financial trades at $73.83 (market cap $23.99B). The key difference: Gilead Sciences, Inc. is far larger — about 7.6× Synchrony Financial's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Synchrony Financial for 28 Days on average.
| GILD | SYF | |
|---|---|---|
Market Cap | $182.40B | $23.99B |
Volume | 4,469,821 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $155.80 | $88.47 |
52-Week Low | $116.74 | $63.78 |
Typical Hold Time | 111 Days | 28 Days |
Enterprise Value | $205.46B | $24.23B |
Dividend Yield | 2.23% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Synchrony Financial (SYF) trades at $71.93, down 0.32% today, with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 23.4% net income margin and 22.23% ROE, trading at attractive valuations (P/E 7.56x). Recent developments include partnerships with OpenAI and Vetspire to expand AI-driven commerce and veterinary financing capabilities, while Q3 2026 earnings are scheduled for October 20, 2026.
SYF presents a compelling value opportunity with strong earnings momentum and analyst consensus target of $87.58 (22% upside). However, technical weakness and increased investing outflows in 2026 create near-term headwinds. The stock offers shareholder returns through dividends and buybacks, but faces risks from consumer credit quality and competitive payment landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
